pre-miRNA Information | |
---|---|
pre-miRNA | mmu-mir-465c-1 |
Genomic Coordinates | chrX: 66825955 - 66826035 |
Description | Mus musculus miR-465c-1 stem-loop |
Comment | None |
RNA Secondary Structure | |
pre-miRNA | mmu-mir-465c-2 |
Genomic Coordinates | chrX: 66832517 - 66832597 |
Description | Mus musculus miR-465c-2 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | mmu-miR-465c-5p |
Sequence | 11| UAUUUAGAAUGGCGCUGAUCUG |32 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | Tfap2b | ||||||||||||||||||||
Synonyms | AI606113, AP-2(beta), E130018K07Rik, Tcfap2b | ||||||||||||||||||||
Description | transcription factor AP-2 beta | ||||||||||||||||||||
Transcript | NM_001025305 | ||||||||||||||||||||
Other Transcripts | NM_009334 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on Tfap2b | |||||||||||||||||||||
3'UTR of Tfap2b (miRNA target sites are highlighted) |
>Tfap2b|NM_001025305|3'UTR 1 AAAAAAAAAAATTAAAGAGAAGGAAAATGTTTTAAATACAAAAGGAAAACAGAAAAAAAATAAATTTAGCTTTAACATAT 81 TGGATTGGCTTTGGAGGAATTATATTAGGTAGAATACACATACAATCAAAATTTAAAAAGAAAGCTAAATAACGTTAAAA 161 AAAAATAAACTGAGGCATACAACGGAGCAACAAACCGGCTCTCGGTGTCTATTTCAAGATACACGTGGAGACAACCGTCC 241 GGATTTTCCACTTCGGTTCTTTCGAATTTAGTAATACAGATAAAAAAGGAAAACTATGAATCCCCCTTTTGGAAAATAAA 321 ACGTGAGACTAAACATGAGAACACGCTAACTTATTGGAAGAAAATTGGAGAAACGTTGGTGTCAATGCTTTTGAGAGCTG 401 GTTGACTGAGACGCACGAACTTTTAAATCTTTAATTTAATTTTTTTTTTTTTTAAGGAAACTCTCGCACTTCGCGCCCTC 481 CATTTCTCCTCATTCTCCTCACCGCTGCTTCCCTTTCTCCCTTCCTCACAGCGATCCCGGAAATCTGCTGGGTGATCACG 561 AGTGTGATTAGCTCTCTGGTGTTAGCCCCTTTGGTGTCCAGACCGCGCCTTGCGTTCCTAACTCCCCTGAGCCCAACTCC 641 CCTACCTCCCCTCCACCCCCACCCTCACCCTCACCCCGCCCCGGTGTGTTTAATTAGGGAGGCCAAGGGTGGGGGTGGGG 721 GACAGGCGGAGGCTCTAGCTTTTGATCCAGGCTTGAGAGCCCAGGCTCCCGCGGCAGAGAGGAAACCGATAAGTTGATTC 801 ATCTTGGTTCCTTTTAGAAAATGTTACTAGTCTCCCAGACGTGACAGCACCTGTTCACAGAGAATATTACATTTGTTATA 881 CTTGTGTCATCTAGCGGTATAGTTTAAAAAGAAAGGAAAAGAAAGGAAAAAACAAAAACCAAAACATGAAAACTTTGATT 961 AGTATGTAATTCCTTCGGAGGGGTATGTACCACTGACTCTCTTCTGTTTCCCCAAGCTTTACCCGCATGGTTTATGAGCT 1041 TCTTCAAGGAAGATTTGGGCTTCCTACACAATCTATAAGGTACTGAGAAACAACAGCAACAACCTGATCCTTTTTAAAGT 1121 TAAAGCCTGCCTGTCAGATTCGGCAGGTTTTACTTCTTTAAAGAAGCTCAAAGAGAATCATTTAGGAAGTGGCCAGTGTT 1201 GGGGGGAGCGGCTTTGGATTTCTTGCTAACACACCTCAACGCAGGAATTCCAGCAGGGGCGGGACACTGCAGAATGCATT 1281 TTAAGGGAGTCGAGTAAGGTATCTTGGCTTTGGGACCTATATTGTAATGGTATTGTCTTTACTGGAAAAATGGATTCCAT 1361 TTCCTTGGGCTCTTTGGGGACTGGATGTTTTAATGGGGGAAAGAAGTAGTTTTGCTGAGTGATTGGGGAAGACAGTCTAT 1441 AAACTACCATGACTCTGCTTTATGAATGAAACAGTTTTCCTTCTCAGACACACAGGTATTTTGGCATAAAATGGTACACA 1521 CACACACACACACACACACACACACACACACACACACACCAGAAACACAAGGCAAAGGGAACGAGATTGTATTTCAACTT 1601 TGAATTCCTGTCTTGATTTATTGGGAATATTCCTAATGGATGAAGTTCCATGAATTTAATGTATCTCTCTTCTCTTAGTC 1681 CAACTTTTTACTGTACCCCATCTTAATATTACCACGAAGTAAAACCGGCACCTTTAGCAAGTTCAAGGAGTAGAGTATTT 1761 GATTGGTGCACACATTTAGTTTGGGTACACTTATTTTTTTTCACCTACCTAGACGGGAACTTTATAAAATCCATTAGGAT 1841 ATATGTTCAGATGTTTTCTGTGATTTACACAGTCCCTTCCCCCAGTAGTCTGGACTCTCAGTATTCCTATCTTTTTCAAT 1921 CCACTTTGAAGCAAGGGAAGGGGTTGAAGTTTTAGGGACCCTCTGAGGGAATCGCTCAAAGGATGAAGGTTGTAAACAAA 2001 AATTGAGGTCAGGCAACATCTCTGCTCCTATCTCTAGCTGCTTCTGAGCCCCATAGGTTTCCAGGACACAGCCCTAGACG 2081 AGGCTGAAAGGAGTAGAAAGGGCAGGAAAAAATACATGTGTGAACTATAGATTCTCATCTTTCCTCAGTTTAGAAGCCCA 2161 CCCCATTTGTCCAAGAACCTGGACGCTTGCATTAGTTGAATTCTGATTGCACGAAGCCAGCAGAAAACACATTGAAAAAC 2241 ATCGTCTCCTTTCCTTGCAGGGCAACGCGCCCCACGCGTGTGACATCGAGAGACGCGATGGATGCGCCTTGCTCTTACTG 2321 TGCAGGTCCTGGGAACATGTGGGCCACTGAAGCCCAGTGGTGTTGAGGACATAGAATCAGCAGCTGCTGAGGGCGCGAGC 2401 CGTACAGGCCCTTCTTGCTCTCGGCCTCACCCTAAGGGCTAAGGCAGCCGCGAAGGGCCGGTTCCCGAGTAGGTAAAGGG 2481 GCGGCGCCCCACTGGCTGCTGCGGGGGAGGGATGCCAGAGCTCTGTAAAGCCATTTTGCCGCAAGCGGTCACTAGGGGCT 2561 CTACTCTCAGAGACCTTGTAGCTTGGAAAAGTCCATGGAATTTGAAACTTCCATGTGTTCTTTATTGCCAGGAAGTGTGG 2641 ACATTTTTTTTAATTGCCTGAAGTGTGGACATGAAATAAGAACTGTCATTCTTGGGTAGGTAGGCTCCCTTAGATGCCCT 2721 GATGTTCCTGTGAGCATCAGCGAAGGGGCAGCTAGATAGACCTGGCTTGAGGCTTCCCTCCCCCATCTCCGGGGTTGTCT 2801 TCTGTTTCTGTTCTTTTTCTCTCTCTTCACGTCGGACCTTTCGCCCCCATGCTTTCCTTAGCCAAGCCGGCTACATTTAT 2881 CTGATAATTGAGTTATTAAAAGATTTGGTTTCCTTGGATTTATAAATCAATAAACAGTAGGATTAACGCAAGAGTTTGCC 2961 TTTTAAGTCAAGGAAAAACGTTTAAGGCCAGGCCCTTTGAGTTTTGTTTTCAAACCAAACAGGTGAGTTACAGTCCTATA 3041 CTCTCCCCTGCACTCTGTAGATGGCTTATCTTATCTAGGCCCGCTCCCACCACCCCCAAGCCCTACCAAATGCCGGGGGT 3121 CCAAAACCAAATAGCTAAAGACTGAAGCGTAGGCCGGTGACTGCTGGAGTTCCCCCAAGGTCCTTGGAGCCCCTTCTTTT 3201 TGAATCAAGCATCCTCCTACTTTTATTCTGAGTCTCATGGAGTTTGTTCCTAGGTGAGGATTCCCTCTCCAGAGACCTTT 3281 AATTTTCATCCCAACTACGAAGTAACTTTCTTTTCTTCTTTTCACCAACTTATCTTGCCCCCCCCCACTTCCTCACTTCC 3361 CCACTTACCTGCCCAAAACCTACTCCTTCTTCCATAGCTTTCTCCACCCCCATATAAAGAGCTCAACGGGCTTTTGAAGA 3441 TCCGACCTTTGTTGGCCTTGGCCAGGAACTTTCTCTTAAGCAATTATTTCATAACCTTTGAAAACTGGTCGAATGGGAAA 3521 CCCCAACCTTCCAACTTTTCTACACACTTCGTTCATGGTTACAAGACCCCTCCCTATTTAGAGTATTGATAGAAAATTCA 3601 TCGCCATACCTGATATCCTGTACTTGTAATACATTCTGTGGGAAGGAACTGATGACCTCAAACCATCAGACTCTGCCTCA 3681 AGTGCTCAGAGAAACAAGAGCTTCCCTCCTTTGCTGATATACATTAAATTATTGGTAAAAGAAAAAAAAACCAGAAGTAT 3761 TGGATTGTTTTCTTAAAACAAAACAAAACAAAAACCCAAAAAACACAAAAAAACAACAAAAACAACGGGGTGAACACCAT 3841 TTCTTCTTTAATGCCAAAACCGTTTCTCCTTTTGAGTTGGCCTTTAATTCAGTACCATTTGTTTTGACCACCCAGTCAAG 3921 AGGTAACAACTGCCTCTTCTCGAGGGCACTCTGGAGGGTATCTGTGTTAAGTTTGTATATATTTATTTATGCTTAATTTA 4001 ATGGGAATGTGTAAATATGATGAGCAAGTAGTTTGGGATTATTTATCTGTGACTCTATACCTCTGTGAATGGGTGGTTTA 4081 AAAGAAAAAAAGAACCGCTTGACCCTAGCTAGAATCCTATTTGAATTCTTCTGTTCTTTATAGACAAGCTGTTATGGTAT 4161 TGGGTAGAAATTGGTTTATTGTCCAGTGTTAATCTGATTTACATAAATAAAAAAGATTGTTGTGTTTTTGTTGTGTTCTC 4241 CTCTTCAGTTCCTTAAACATAAAGATTGTTCCATTCTACAGACAGAAACAAAGATATAGCAAAAAAGATTTCTTCCTTTT 4321 GCACCCCCGCCACAGACGTACATACAGTGTTTTTGTTACAACAGAAATATAATAAATTTTGCATATCAGAAAAATGAACA 4401 CTTTTATTTCCAGTAGGAGGTGCTTTTTAAAAAACTCTTAAAACTTCAAATGGATACTAGTCCCAATCATATTTGTAATA 4481 AAAGTTCATGTTAACTGC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | CD4+ T cells (C57BL/6) |
Disease | MIMAT0004873 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"HITS-CLIP data was present in GSM1013595. RNA binding protein: AGO2. Condition:CD4+ T cells
... - Loeb GB; Khan AA; Canner D; Hiatt JB; et al., 2012, Molecular cell. |
Article |
- Loeb GB; Khan AA; Canner D; Hiatt JB; et al. - Molecular cell, 2012
MicroRNAs (miRNAs) are essential components of gene regulation, but identification of miRNA targets remains a major challenge. Most target prediction and discovery relies on perfect complementarity of the miRNA seed to the 3' untranslated region (UTR). However, it is unclear to what extent miRNAs target sites without seed matches. Here, we performed a transcriptome-wide identification of the endogenous targets of a single miRNA-miR-155-in a genetically controlled manner. We found that approximately 40% of miR-155-dependent Argonaute binding occurs at sites without perfect seed matches. The majority of these noncanonical sites feature extensive complementarity to the miRNA seed with one mismatch. These noncanonical sites confer regulation of gene expression, albeit less potently than canonical sites. Thus, noncanonical miRNA binding sites are widespread, often contain seed-like motifs, and can regulate gene expression, generating a continuum of targeting and regulation.
LinkOut: [PMID: 23142080]
|
20 mmu-miR-465c-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT577524 | Tirap | toll-interleukin 1 receptor (TIR) domain-containing adaptor protein | 2 | 2 | ||||||||
MIRT578756 | Gm11559 | predicted gene 11559 | 2 | 2 | ||||||||
MIRT579164 | Cdc37 | cell division cycle 37 | 2 | 2 | ||||||||
MIRT579596 | 4930563E22Rik | RIKEN cDNA 4930563E22 gene | 2 | 2 | ||||||||
MIRT579614 | 4930430F08Rik | RIKEN cDNA 4930430F08 gene | 2 | 2 | ||||||||
MIRT581042 | Sim1 | single-minded homolog 1 (Drosophila) | 2 | 2 | ||||||||
MIRT581082 | Setd7 | SET domain containing (lysine methyltransferase) 7 | 2 | 2 | ||||||||
MIRT582172 | Nkain3 | Na+/K+ transporting ATPase interacting 3 | 2 | 4 | ||||||||
MIRT582549 | Map3k1 | mitogen-activated protein kinase kinase kinase 1 | 2 | 2 | ||||||||
MIRT585014 | Gid4 | GID complex subunit 4, VID24 homolog | 1 | 2 | ||||||||
MIRT585345 | Ybey | ybeY metallopeptidase | 2 | 2 | ||||||||
MIRT585446 | Veph1 | ventricular zone expressed PH domain-containing 1 | 2 | 2 | ||||||||
MIRT585687 | Tbc1d24 | TBC1 domain family, member 24 | 2 | 2 | ||||||||
MIRT588450 | Ybx1 | Y box protein 1 | 2 | 4 | ||||||||
MIRT592140 | Ppp1r1c | protein phosphatase 1, regulatory (inhibitor) subunit 1C | 2 | 2 | ||||||||
MIRT593134 | Thrb | thyroid hormone receptor beta | 2 | 4 | ||||||||
MIRT594593 | Tfap2b | transcription factor AP-2 beta | 1 | 1 | ||||||||
MIRT595796 | Dapk1 | death associated protein kinase 1 | 2 | 2 | ||||||||
MIRT595818 | Arl4a | ADP-ribosylation factor-like 4A | 2 | 2 | ||||||||
MIRT598674 | Hltf | helicase-like transcription factor | 2 | 2 |